This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human HABP1 / C1QBP Protein, His Tag
catalog :
C1P-H5122
quantity :
100 ug, 1 mg
price :
180 USD, 1100 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
C1P-H5122
product name :
Human HABP1 / C1QBP Protein, His Tag
quantity :
100 ug, 1 mg
price :
180 USD, 1100 USD
quantity & price :
$180/100ug,$1100/1mg (200ug × 5)
target :
HABP1
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human HABP1, His Tag (C1P-H5122) is expressed from E.coli cells. It contains AA His 75 - Gln 282 (Accession # Q07021-1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human HABP1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Complement component 1 Q subcomponent-binding protein, mitochondrial (C1QBP), a member of the MAM33 family, is also known as ASF/SF2-associated protein p32, glycoprotein gC1qBP (C1qBP), mitochondrial matrix protein p32 and hyaluronan-binding protein 1, which is a homotrimer that contains three monomers forming a donut-shaped structure with an unusually asymmetric charge distribution on the surface. C1q associates with C1r and C1s in order to yield the first component of the serum complement system. C1QBP has also been identified as the p32 subunit of pre-mRNA splicing factor SF2, as well as a hyaluronic acid-binding protein. Furthermore, C1QBP has been shown to interact with Protein kinase D1, BAT2, PRKCD, PKC alpha and Protein kinase Mζ .
References :
(1) Krainer A.R., et al., 1990, Cell 66:383-394.
(2) Deb T.B., et al., 1995, J. Biol. Chem. 271:2206-2212.
(3) Joseph K., et al., 1998, Clin. Immunol. 92:246-255.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments